The efficacy and safety of iGlarLixi versus IDegAsp in Chinese people with type 2 diabetes suboptimally controlled with oral antidiabetic drugs: The Soli‐D randomized controlled trial
In Chinese people with T2D suboptimally controlled with OADs, once-daily iGlarLixi provided better glycaemic control with BW benefit and lower hypoglycaemia event rates versus IDegAsp.
PDF的下载单位、IP信息已删除
(2025-6-4)
无极微光
张欢馨
zzzz
大力的灵雁
pluto
你嵙这个期刊没买
畔畔
贪玩的秋柔
Criminology34
GingerF
1111
HEAR
辛勤的傲芙
嘉心糖
科研狗
子车茗
干净的琦
pcr163
双持裤衩武器战
iNk
皖公网安备34019202002308
